West Family Investments’s Royalty Pharma RPRX Stock Holding History

West Family Investments’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$240K	Buy	+4,288	New	+$223K	0.07%	391

Other funds holding RPRX

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

West Family Investments's RPRX Position: Q2 2026 in Review

West Family Investments opened a new position in Royalty Pharma (RPRX) in Q2 2026: 4,288 shares worth $240K. The stake represents 0.07% of the portfolio and ranks #391 among its holdings.

418 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

West Family Investments held 4,288 shares of Royalty Pharma worth $240K as of Q2 2026.
Royalty Pharma was a new West Family Investments position in Q2 2026.
Royalty Pharma made up 0.07% of West Family Investments's portfolio in Q2 2026, its #391 holding.
418 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on West Family Investments's 13F filing for Q2 2026, filed 10 Aug 2026.